-
Mashup Score: 0
The Claudin18.2 antibody-drug conjugate IBI343 is well tolerated and shows encouraging efficacy in patients with PDAC.
Source: www.gioncologynow.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 0
Dr. Wainberg details the practice-changing implications of the MATTERHORN study event-free survival data.
Source: www.gioncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
📺 Dr. Zev Wainberg of @UCLAHealth details the practice-changing implications of the MATTERHORN study's EFS data in a new interview: https://t.co/z2g0N4KaYC 👉 MATTERHORN examined the efficacy of a #durvalumab combination treatment in for resectable gastric/GEJ cancer. https://t.co/Xnw7MqegPw
-
-
Mashup Score: 0
The ATOMIC trial showed that adding atezo to mFOLFOX6 significantly improves DFS in stage III colon cancer and dMMR.
Source: www.gioncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
🔎 The phase 3 ATOMIC trial has demonstrated that adding #atezolizumab to standard adjuvant mFOLFOX6 chemotherapy can significantly improve disease-free survival in patients with stage 3 #coloncancer: https://t.co/OXRbNwj7Vh
-
-
Mashup Score: 1
The findings are considered practice changing and support EC+mFOLFOX6 as a new SOC for BRAF V600E-mutant mCRC.
Source: www.gioncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
👉 Results from the phase 3 #BREAKWATER trial were presented by Dr. Elena Elez of @VHIO at @ASCO #ASCO25, demonstrating that #encorafenib/cetuximab/FOLFOX is practice-changing as a new standard of care for BRAF V600E-mutated metastatic #colorectalcancer: https://t.co/4fjlGKrue2
-
-
Mashup Score: 11
Dr. Joseph McCollom discusses his path to specialization in GI cancers and the pivotal role of palliative care in oncology.
Source: www.gioncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
🤝 At @ParkviewHealth Packnett Family Cancer Institute, @realbowtiedoc leads efforts to integrate palliative care into oncology practice to enhance patient support. 📰 Learn about Dr. McCollom's path to specialization in GI cancers in our new interview: https://t.co/8RqnU75G8a
-
-
Mashup Score: 0
Adjuvant nivolumab provides durable long-term DFS benefit and shows an OS advantage in patients with resected EC/GEJC.
Source: www.gioncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
👀 We have a behind-the-scenes look of our interview at @ASCO with @DrRonanKelly on the CheckMate 577 trial. Read our coverage to find out more: https://t.co/wxxBYSG6zG #ASCO25 https://t.co/kKwT4EzyFX
-
-
Mashup Score: 2
Long-term follow-up from KEYNOTE-016 explores pembrolizumab treatment in dMMR/MSI-H solid tumors in advanced CRC.
Source: www.gioncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
⏰ Coming up at @ASCO #ASCO25: 10-year survival outcomes of KEYNOTE-016 and the benefit of #pembrolizumab for dMMR/MSI-H solid tumors: https://t.co/dd6L5bKMSx 👉 Watch Dr. Katherine M. Bever of @HopkinsMedicine present this new data in Hall D2 at 12:36 pm CDT tomorrow.
-
-
Mashup Score: 2ASCO 2025 Annual Meeting | GI Oncology Now - 11 day(s) ago
Review the latest news and research updates for GI cancer from the ASCO 2025 Annual Meeting.
Source: www.gioncologynow.comCategories: General Medicine News, UrologyTweet-
⭐ Get ready for day 1 of #ASCO25 by previewing upcoming presentations on the latest data in #colorectal, #gastric, and #liver cancer research at our conference coverage page: https://t.co/8iqpaHfymo
-
-
Mashup Score: 0
Pembro plus lenvatinib with chemo may improve progression-free survival in patients when compared with the standard of care.
Source: www.gioncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
⭐ Get a first look at Dr. Sun Rha’s recent presentation from #ASCO25 on the phase 3 randomized LEAP-015 study that examined the combination of #pembrolizumab, #lenvatinib, and chemotherapy for advanced gastroesophageal adenocarcinoma: https://t.co/iwKzGOEiNS
-
-
Mashup Score: 0
Researchers evaluated the efficacy and safety of hepatic arterial infusion chemotherapy as a first-line treatment option.
Source: www.gioncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
📋 Learn more about a recent study that investigated the effectiveness of hepatic arterial infusion chemo with donafenib and tislelizumab for patients with hepatocellular carcinoma. Read more about the findings here: https://t.co/PpTiQfn4zX
-
👉 According to data presented at #ASCO25, the Claudin18.2 antibody-drug conjugate IBI343 is well tolerated and continues to show encouraging efficacy in patients with #pancreatic ductal adenocarcinoma: https://t.co/STwYflN0xC